Bionano Genomics, Inc.
BNGOHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bionano Genomics, Inc. focuses on Medical Instruments & Supplies services and products. Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. Valued at $13.3M, BNGO is a micro-cap name in its sector. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Market Cap
$13.3M
Beta
1.66
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-2.85
EPS (Fwd)
$-0.97
ROE
-83.6%
ROA
-32.6%
Cash
$9.9M
Total Debt
$6.7M
Free CF
$2.3M
52W Change
-41.4%
Annual Financials
Cash vs Debt
Where BNGO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BNGO finished 2.40% below its 150-day moving average ($1.25) and 3.17% below its 200-day moving average ($1.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNGO overbought or oversold?
At the October 20, 2026 close, BNGO's RSI(14) was 6.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bionano Genomics, Inc. holds $9.9M in cash against $6.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $2.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -83.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $27.8M (2022) to $28.5M (2025).
A beta of 1.66 means BNGO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bionano Genomics, Inc. and its sector.